Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case

Kouji Andou, Eiji Oki, Masahiko Sugiyama, Yan Zhao, Aya Kojima, Hidetaka Yamamoto, Yoichi Yamashita, Hiroshi Saeki, Akinobu Taketomi, Masaru Morita, Yoshihiro Kakeji, Shunichi Tsujitani, Yoshihiko Maehara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.

Original languageEnglish
Pages (from-to)1290-1293
Number of pages4
JournalSurgery today
Volume41
Issue number9
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

Gastrointestinal Stromal Tumors
Genes
Mutation
Neoplasm Metastasis
Neoplasms
Abdominal Cavity
Liver
Therapeutics
Gastrointestinal Tract
Exons
Clone Cells
Imatinib Mesylate
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate : Report of a case. / Andou, Kouji; Oki, Eiji; Sugiyama, Masahiko; Zhao, Yan; Kojima, Aya; Yamamoto, Hidetaka; Yamashita, Yoichi; Saeki, Hiroshi; Taketomi, Akinobu; Morita, Masaru; Kakeji, Yoshihiro; Tsujitani, Shunichi; Maehara, Yoshihiko.

In: Surgery today, Vol. 41, No. 9, 01.09.2011, p. 1290-1293.

Research output: Contribution to journalArticle

Andou, K, Oki, E, Sugiyama, M, Zhao, Y, Kojima, A, Yamamoto, H, Yamashita, Y, Saeki, H, Taketomi, A, Morita, M, Kakeji, Y, Tsujitani, S & Maehara, Y 2011, 'Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case', Surgery today, vol. 41, no. 9, pp. 1290-1293. https://doi.org/10.1007/s00595-010-4477-8
Andou, Kouji ; Oki, Eiji ; Sugiyama, Masahiko ; Zhao, Yan ; Kojima, Aya ; Yamamoto, Hidetaka ; Yamashita, Yoichi ; Saeki, Hiroshi ; Taketomi, Akinobu ; Morita, Masaru ; Kakeji, Yoshihiro ; Tsujitani, Shunichi ; Maehara, Yoshihiko. / Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate : Report of a case. In: Surgery today. 2011 ; Vol. 41, No. 9. pp. 1290-1293.
@article{88f7346d912f4d4cb6f1eeff4246570b,
title = "Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case",
abstract = "Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.",
author = "Kouji Andou and Eiji Oki and Masahiko Sugiyama and Yan Zhao and Aya Kojima and Hidetaka Yamamoto and Yoichi Yamashita and Hiroshi Saeki and Akinobu Taketomi and Masaru Morita and Yoshihiro Kakeji and Shunichi Tsujitani and Yoshihiko Maehara",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/s00595-010-4477-8",
language = "English",
volume = "41",
pages = "1290--1293",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "9",

}

TY - JOUR

T1 - Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate

T2 - Report of a case

AU - Andou, Kouji

AU - Oki, Eiji

AU - Sugiyama, Masahiko

AU - Zhao, Yan

AU - Kojima, Aya

AU - Yamamoto, Hidetaka

AU - Yamashita, Yoichi

AU - Saeki, Hiroshi

AU - Taketomi, Akinobu

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Tsujitani, Shunichi

AU - Maehara, Yoshihiko

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.

AB - Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.

UR - http://www.scopus.com/inward/record.url?scp=80052416180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052416180&partnerID=8YFLogxK

U2 - 10.1007/s00595-010-4477-8

DO - 10.1007/s00595-010-4477-8

M3 - Article

C2 - 21874433

AN - SCOPUS:80052416180

VL - 41

SP - 1290

EP - 1293

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 9

ER -